AGM Results
Dublin, London | 12 May 2021
Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 12 May 2021, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.
Details of votes cast are set out below:
| | RESOLUTION | TOTAL | FOR | % | AGAINST | % | ABSTAIN |
| 1 | Financial Statements and Reports | 137,296,226 | 135,574,392 | 98.75 | 1,721,834 | 1.25 | 20,532 |
| 2 | Final Dividend of €4.2m | 137,296,226 | 137,293,095 | 100.00 | 3,131 | 0.00 | 20,532 |
| 3(a) | Re-elect Tim Dolphin | 137,316,758 | 137,242,840 | 99.95 | 73,918 | 0.05 | 0 |
| 3(b) | Re-elect Padraic Dempsey | 137,316,758 | 137,242,840 | 99.95 | 73,918 | 0.05 | 0 |
| 3(c) | Re-elect Paul Hogan | 137,316,758 | 136,410,522 | 99.34 | 906,236 | 0.66 | 0 |
| 3(d) | Re-elect Maurice Pratt | 137,316,758 | 137,219,247 | 99.93 | 97,511 | 0.07 | 0 |
| 4(a) | Elect Jeff Berkowitz | 137,316,758 | 137,284,424 | 99.98 | 32,334 | 0.02 | 0 |
| 4(b) | Elect Jim Gaul | 137,316,758 | 137,284,424 | 99.98 | 32,334 | 0.02 | 0 |
| 4(c) | Elect Liz Hoctor | 137,316,758 | 137,293,695 | 99.98 | 23,063 | 0.02 | 0 |
| 5 | Remuneration of Auditors | 125,264,944 | 119,641,181 | 95.51 | 5,623,763 | 4.49 | 12,051,814 |
| 6 | Allot relevant securities | 137,296,100 | 135,196,092 | 98.47 | 2,100,008 | 1.53 | 20,658 |
| 7 | Disapplication of pre-emption rights in specified circumstances | 137,264,600 | 137,241,537 | 99.98 | 23,063 | 0.02 | 52,158 |
| 8 | Disapplication of pre-emption rights in additional circumstances | 137,264,600 | 137,185,914 | 99.94 | 78,686 | 0.06 | 52,158 |
| 9 | Authorise market purchases of the Company's Ordinary Shares | 137,304,627 | 137,281,564 | 99.98 | 23,063 | 0.02 | 12,131 |
| 10 | Re-issuance of Treasury Shares | 137,304,627 | 137,281,564 | 99.98 | 23,063 | 0.02 | 12,131 |
--- ENDS ---
For further details contact:
| Uniphar | +353 (0) 1 428 7777 |
| | |
| Brian O'Shaughnessy | |
| Group Director of Corporate Development | |
| | |
|
Davy |
+353 (0) 1 679 6363 |
| (Joint Broker, Nominated Adviser and Euronext Growth Adviser) | |
| | |
| Fergal Meegan | |
| Barry Murphy | |
| Niall Gilchrist | |
| | |
| RBC Capital Markets (Joint Broker) | +44 (0) 20 7653 4000 |
| | |
| Jonathan Hardy | |
| Jamil Miah Priyal Soni
| |
| Stifel Nicolaus Europe Limited (Joint Broker) | +44 (0) 20 7710 7600 |
| Matt Blawat | |
| Ben Maddison | |
| Francis North | |
| | |
| Q4 PR | +353 (0) 1 475 1444 or |
| (Public Relations Adviser to Uniphar) | +353 87 235 6461 |
| | |
| Iarla Mongey | |
About Uniphar plc
Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.
Product Access
n Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.